Displaying 21 - 25 of 50
Tue 23 June 2015
Today the National Institute for Health and Care Excellence (NICE) has published new Referral Guidelines for Suspected Cancer. David Park, Head of Policy and Campaigns at Pancreatic Cancer UK, comments.Read More about 'Comment on new NICE Referral Guidelines for Suspected Cancer'
Thu 16 April 2015
We're pleased to report that we (Pancreatic Cancer UK) have signed up in support of Cancer Focus Northern Ireland’s Equal Access to Drugs Campaign.Read More about 'Pancreatic Cancer UK supports Cancer Focus NI's Equal Access to Drugs Campaign'
Thu 26 March 2015
Last year, alongside a number of other cancer charities, we campaigned to save the National Cancer Peer Review Programme.Read More about 'NHS England will continue to assess quality of cancer services'
Mon 12 January 2015
National charity Pancreatic Cancer UK says patients feel relieved that Abraxane® – hailed as the first breakthrough drug for pancreatic cancer in 20 years - will not be immediately removed from the Cancer Drugs Fund (CDF) List.Read More about ''Cautiously optimistic': Abraxane will not be removed from the CDF'
Tue 30 December 2014
NICE has today confirmed that it has not recommended Abraxane for use by the NHS in England for patients with metastatic pancreatic cancer, on cost grounds. This decision will also affect patients in Northern Ireland.Read More about 'NICE says NO to Abraxane for advanced pancreatic cancer'